Sponsor
Sponsor
PLORVO
Find Out More
Foundations of Pharmacological Treatment in Obesity & Type 2 Diabetes – 1 CME Point
Speaker
Mr. Yousef Ahmed
Yousaf Ahmad is a highly versatile senior executive healthcare professional known for his board-level leadership and transformational impact across large, complex healthcare organizations. With a proven track record in both NHS and corporate settings, he brings together expertise in clinical care, governance, and international pharmacy to design and deliver innovative strategies that improve efficiency, productivity, and patient outcomes. Yousaf’s strengths, as recognized by Strengthscope, include collaboration, compassion, creativity, developing others, empathy, self-improvement, and strategic-mindedness. Currently, Yousaf serves in multiple high-profile roles, including Non-executive Director, Expert Advisory Board Member, Digital Healthcare Expert, Global Pharmacy Ambassador, School Governor, and University Educator. He is especially valued for his deep knowledge in pharmaceutical practice, digital health, educational models, and for his insight into board and corporate governance at the highest level.
AGENDA
- 40 minutes presentation and then 20 minutes Q&A with the host Nathan Nagel
Outline
- Obesity as a chronic relapsing disease
- Pathophysiology across ethnic groups
- UK BMI thresholds vs cardiometabolic risk
- Role of metformin and legacy agents
- When lifestyle alone is insufficient
- Case examples: South Asian vs White British risk profiles
Learning Objectives
- Describe obesity as a chronic, relapsing metabolic disease and its relationship to type 2 diabetes.
- Explain ethnic differences in cardiometabolic risk, including lower BMI thresholds in South Asian populations.
- Compare mechanisms and weight effects of traditional glucose-lowering agents (e.g. metformin, sulfonylureas, insulin).
- Identify when pharmacological escalation is appropriate within UK primary care pathways.
- Apply culturally informed risk assessment when initiating therapy